AAAAAA
Results: 1-25/46
Authors:
BOLIS G
SCARFONE G
VILLA A
MANGILI G
PIRIETTI E
POLATTI A
REINA S
SPATTI GB
Citation: G. Bolis et al., PHASE-I STUDY OF TOPOTECAN (T) AND EPIRUBICIN (E) IN ADVANCED EPITHELIAL OVARIAN-CANCER (OVCA) RESISTANT OR REFRACTORY TO PACLITAXEL AND CARBOPLATIN (PC) FIRST LINE CHEMOTHERAPY, Annals of oncology, 9, 1998, pp. 331-331
Authors:
BOOKMAN MA
MALMSTROM H
BOLIS G
GORDON A
LISSONI A
KREBS JB
FIELDS SZ
Citation: Ma. Bookman et al., TOPOTECAN FOR THE TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER - AN OPEN-LABEL PHASE-II STUDY IN PATIENTS TREATED AFTER PRIOR CHEMOTHERAPY THAT CONTAINED CISPLATIN OR CARBOPLATIN AND PACLITAXEL, Journal of clinical oncology, 16(10), 1998, pp. 3345-3352
Authors:
BOLIS G
ZAPPALA A
VILLA A
POLATTI A
REINA S
PIRLETTI E
Citation: G. Bolis et al., GUIDELINES FOR EPITHELIAL OVARIAN-TUMORS, Tumori, 84(3), 1998, pp. 23-31
Authors:
SILVESTRINI R
DAIDONE MG
VENERONI S
BENINI E
SCARFONE G
ZANABONI F
VILLA A
PRESTI M
DANESE S
BOLIS G
Citation: R. Silvestrini et al., THE CLINICAL PREDICTIVITY OF BIOMARKERS OF STAGE III-IV EPITHELIAL OVARIAN-CANCER IN A PROSPECTIVE RANDOMIZED TREATMENT PROTOCOL, Cancer, 82(1), 1998, pp. 159-167
Authors:
AABO K
ADAMS M
ADNITT P
ALBERTS DS
ATHANAZZIOU A
BARLEY V
BELL DR
BIANCHI U
BOLIS G
BRADY MF
BRODOVSKY HS
BRUCKNER H
BUYSE M
CANETTA R
CHYLAK V
COHEN CJ
COLOMBO N
CONTE PF
CROWTHER D
EDMONSON JH
GENNATAS C
GILBEY E
GORE M
GUTHRIE D
KAYE SB
LAING AH
LANDONI F
LEONARD RC
LEWIS C
LIU PY
MANGIONI C
MARSONI S
MEERPOHL H
OMURA GA
PARMAR MKB
PATER J
PECORELLI S
PRESTI M
SAUERBREI W
SKARLOS DV
SMALLEY RV
SOLOMON HJ
STEWART LA
STURGEON JFG
TATTERSALL MHN
WHARTON JT
HUININK WWT
TOMIROTTI M
TORRI W
TROPE C
TURBOW MM
VERMORKEN JB
WEBB MJ
WILBUR DW
WILLIAMS CJ
WILTSHAW E
YEAP BY
Citation: K. Aabo et al., CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - 4 SYSTEMATIC METAANALYSES OF INDIVIDUAL PATIENT DATA FROM 39 RANDOMIZED TRIALS, British Journal of Cancer, 78(11), 1998, pp. 1479-1487
Authors:
PARAZZINI F
CHATENOUD L
LAVECCHIA C
NEGRI E
FRANCESCHI S
BOLIS G
Citation: F. Parazzini et al., DETERMINANTS OF RISK OF INVASIVE CERVICAL-CANCER IN YOUNG-WOMEN, British Journal of Cancer, 77(5), 1998, pp. 838-841
Authors:
VILLA A
PARAZZINI F
ACERBONI S
GUARNERIO P
BOLIS G
Citation: A. Villa et al., SURVIVAL AND PROGNOSTIC FACTORS OF EARLY OVARIAN-CANCER, British Journal of Cancer, 77(1), 1998, pp. 123-124
Authors:
PARAZZINI F
LAVECCHIA C
NEGRI E
FRANCESCHI S
MORONI S
CHATENOUD L
BOLIS G
Citation: F. Parazzini et al., CASE-CONTROL STUDY OF ESTROGEN REPLACEMENT THERAPY AND RISK OF CERVICAL-CANCER, BMJ. British medical journal, 315(7100), 1997, pp. 85-88
Authors:
VANDERBURG MEL
BOLIS G
BAKKER PJM
CURRAN D
SAHMOUD T
VERMORKEN JB
Citation: Mel. Vanderburg et al., PHASE-II STUDY OF WEEKLY 4'-EPIDOXORUBICIN IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE CERVIX - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY, European journal of cancer, 33(9), 1997, pp. 1513-1515
Authors:
RUSTIN GJS
NELSTROP AE
BOLIS G
GORE M
TENBOKKELHUININK W
SPACZYNSKI M
Citation: Gjs. Rustin et al., RESPONSE AND EARLY PROGRESSION ACCORDING TO CA-125 TO ASSESS ACTIVITYOF TOPOTECAN VS PACLITAXEL IN RELAPSED OVARIAN-CARCINOMA, European journal of cancer, 33, 1997, pp. 525-525
Authors:
CANEVARI S
NEGRI DRM
CALABRESE M
SILIPRANDI V
BOTTI C
SEREGNI E
COLNAGHI MI
BOLIS G
Citation: S. Canevari et al., T-CELL RETARGETING FOR LOCAL AND SYSTEMIC CONTROL OF DISEASE, European journal of cancer, 33, 1997, pp. 620-620
Authors:
BOLIS G
SCARFONE G
ZANABONI F
VILLA A
PRESTI M
MELPIGNANO M
FERRARIS C
TATEO S
GUARNERIO P
GENTILE A
PARAZZINI F
Citation: G. Bolis et al., A PHASE I-II TRIAL OF FIXED-DOSE CARBOPLATIN AND ESCALATING PACLITAXEL IN ADVANCED OVARIAN-CANCER, European journal of cancer, 33(4), 1997, pp. 592-595
Authors:
PARAZZINI F
MORONI S
LAVECCHIA C
NEGRI E
DALPINO D
BOLIS G
Citation: F. Parazzini et al., OVARIAN-CANCER RISK AND HISTORY OF SELECTED MEDICAL CONDITIONS LINKEDWITH FEMALE HORMONES, European journal of cancer, 33(10), 1997, pp. 1634-1637
Authors:
BOLIS G
FERRARIS C
PARAZZINI F
Citation: G. Bolis et al., IS ABDOMINOPELVIC RADIATION-THERAPY THE OPTIMAL TREATMENT FOR COMPLETELY RESECTED STAGE-I AND STAGE-II HIGH-RISK OVARIAN-CANCER - CONTRA, European journal of cancer, 33(1), 1997, pp. 15-17
Authors:
GWYTHER S
BOLIS G
GORE M
HUININK WT
VERWEIJ J
HUDSON IR
DESPAX R
JIMENEZLACAVE A
Citation: S. Gwyther et al., EXPERIENCE WITH INDEPENDENT RADIOLOGICAL REVIEW DURING A TOPOTECAN TRIAL IN OVARIAN-CANCER, Annals of oncology, 8(5), 1997, pp. 463-468
Authors:
HUININK WTB
GORE M
CARMICHAEL J
GORDON A
MALFETANO J
HUDSON I
BROOM C
SCARABELLI C
DAVIDSON N
SPANCZYNSKI M
BOLIS G
MALMSTROM H
COLEMAN R
FIELDS SC
HERON JF
Citation: Wtb. Huinink et al., TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER, Journal of clinical oncology, 15(6), 1997, pp. 2183-2193
Authors:
BOLIS G
FAVALLI G
DANESE S
ZANABONI F
MANGILI G
SCARABELLI C
TATEO S
VALSECCHI MG
SCARFONE G
RICHIARDI G
FRIGERIO I
MELPIGNANO M
VILLA A
PARAZZINI F
Citation: G. Bolis et al., WEEKLY CISPLATIN GIVEN FOR 2 MONTHS VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE GIVEN FOR 5 MONTHS AFTER CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER, Journal of clinical oncology, 15(5), 1997, pp. 1938-1944
Authors:
CANEVARI S
MEZZANZANICA D
MAZZONI A
NEGRI DRM
FIGINI M
RAMAKRISHNA V
BOLIS G
COLNAGHI MI
Citation: S. Canevari et al., APPROACHES TO IMPLEMENT BISPECIFIC ANTIBODY TREATMENT OF OVARIAN-CARCINOMA, Cancer immunology and immunotherapy, 45(3-4), 1997, pp. 187-189
Authors:
BOLIS G
SCARFONE G
VILLA A
ACERBONI S
SILIPRANDI V
GUARNERIO P
Citation: G. Bolis et al., A PHASE-I TRIAL WITH FIXED-DOSE CARBOPLATIN AND ESCALATING DOSES OF PACLITAXEL IN ADVANCED OVARIAN-CANCER, Seminars in oncology, 24(1), 1997, pp. 23-25
Authors:
HEIDEMPERGHER F
PILLAN A
PINCIROLI V
VAGHI F
ARRIGONI C
BOLIS G
CACCIA C
DHO L
MCARTHUR R
VARASI M
Citation: F. Heidempergher et al., PHENYLIMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE 5-HT3 RECEPTOR ANTAGONISTS AND REFINEMENT OF THE PHARMACOPHORE MODEL FOR 5-HT3 RECEPTOR-BINDING, Journal of medicinal chemistry, 40(21), 1997, pp. 3369-3380
Authors:
RAMAKRISHNA V
NEGRI DRM
BRUSIC V
FONTANELLI R
CANEVARI S
BOLIS G
CASTELLI C
PARMIANI G
Citation: V. Ramakrishna et al., GENERATION AND PHENOTYPIC CHARACTERIZATION OF NEW HUMAN OVARIAN-CANCER CELL-LINES WITH THE IDENTIFICATION OF ANTIGENS POTENTIALLY RECOGNIZABLE BY HLA-RESTRICTED CYTOTOXIC T-CELLS, International journal of cancer, 73(1), 1997, pp. 143-150
Authors:
BERGQVIST D
ELDOR A
THORLACIUSUSSING O
COMBE S
COSSECVION MJ
GARDINER G
GAUX JC
TOOULI J
CADE J
VIELLE G
BOESBY S
VARON D
BOLIS G
PERACHIA A
BONAVINA L
PIETRI P
HORN A
REIERTSEN O
WIIG J
BONNIN JB
NORGREN L
PALSSON B
TORNQVIST A
WIGGERS T
LYONS RM
NYAMUSWA G
SMINK RD
TROWBRIDGE A
GREENSPOON J
HAIRE WD
JOYCE C
KOCH MO
LEVENBACK C
FIORICA J
MOWLER J
GREEN D
BODENSTEINER D
COHEN A
COMP P
DOCKENDORF B
Citation: D. Bergqvist et al., EFFICACY AND SAFETY OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN FOR PREVENTION OF DEEP-VEIN THROMBOSIS IN ELECTIVE CANCER-SURGERY - A DOUBLE-BLIND RANDOMIZED MULTICENTER TRIAL WITH VENOGRAPHIC ASSESSMENT, British Journal of Surgery, 84(8), 1997, pp. 1099-1103
Authors:
NICASTRO G
BAUMER L
BOLIS G
TATO M
Citation: G. Nicastro et al., NMR SOLUTION STRUCTURE OF A NOVEL HIRUDIN VARIANT-HM2, N-TERMINAL-1-47 AND N64-]V-MUTANT(G), Biopolymers, 41(7), 1997, pp. 731-749
Authors:
DAIDONE MG
BENINI E
VALENTINIS B
BOLIS G
VILLA A
SILVESTRINI R
Citation: Mg. Daidone et al., P53 EXPRESSION, DNA CONTENT AND CELL-PROLIFERATION IN PRIMARY AND SYNCHRONOUS METASTATIC LESIONS FROM OVARIAN SURFACE EPITHELIAL-STROMAL TUMORS, European journal of cancer, 32A(8), 1996, pp. 1388-1393
AN EORTC RANDOMIZED TRIAL OF DOXORUBICIN+ -CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA/
Authors:
AAPRO M
SAHMOUD T
TEODOROVIC I
BOLIS G
CHEVALLIER B
VANDERBURG M
POVEDA A
DEOLIVEIRA C
PECORELLI S
Citation: M. Aapro et al., AN EORTC RANDOMIZED TRIAL OF DOXORUBICIN+ -CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA/, Journal of clinical oncology, 14(5), 1996, pp. 2014-2014